Last updated: 2026-10-13 15:22:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Dianthus Therapeutics, Inc. (DNTH) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $79,34, with a market capitalization of $4,61B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $32,22 to $117,88. This page covers its latest market performance, valuation, price trends and company information.
$4,61B | |
$81,42 | |
$117,88 | |
$6,58 | |
$81,57 | |
110,34K | |
796,56K | |
-- | |
$117,88 | |
$32,22 | |
-- | |
-- |
Dianthus Therapeutics, Inc. (DNTH) is currently trading at $79,34 as of 2026-10-13 15:21:00, down 2,73% ($2,23) from the previous close of $81,57
During today's regular trading session, DNTH has traded between $6,58 and $117,88, with a trading volume of 110,34K shares. The current price is near the upper end of today's range.
Over the past seven days, Dianthus Therapeutics, Inc. (DNTH) moved from $88,21 to $79,34, representing a decline of 10,06% ($8,87).
The stock traded between $79,00 and $91,24 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 836,51 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 55,0%
DNTH is currently trading at $79,34, placing it 55,0% of the way from its 52-week low of $32,22 to its 52-week high of $117,88. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 92 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Dianthus Therapeutics, Inc. (DNTH) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.